Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects
Robert D Steigerwalt Jr1, Gianni Belcaro1, Paolo Morazzoni2, Ezio Bombardelli2, Carolina Burki3, Frank Schönlau4 1Department of Biomedical Sciences, University of Chieti-Pescara, San Valentino, Italy; 2Indena S.p.A. Scientific Department, Milan, Italy; 3Horphag Research (UK) Ltd., Genev...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/f006189deaa4460a93eedfacea0c2992 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:f006189deaa4460a93eedfacea0c2992 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:f006189deaa4460a93eedfacea0c29922021-12-02T04:21:23ZMirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects1177-54671177-5483https://doaj.org/article/f006189deaa4460a93eedfacea0c29922010-05-01T00:00:00Zhttp://www.dovepress.com/mirtogenolreg-potentiates-latanoprost-in-lowering-intraocular-pressure-a4426https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Robert D Steigerwalt Jr1, Gianni Belcaro1, Paolo Morazzoni2, Ezio Bombardelli2, Carolina Burki3, Frank Schönlau4 1Department of Biomedical Sciences, University of Chieti-Pescara, San Valentino, Italy; 2Indena S.p.A. Scientific Department, Milan, Italy; 3Horphag Research (UK) Ltd., Geneva, Switzerland; 4Horphag Research (UK) Ltd. South Kensington, London UKPurpose: The dietary supplement Mirtogenol® was previously shown to lower elevated intraocular pressure (IOP). We here present the effects of this supplement on IOP in comparison as well as in combination with latanoprost eye drops. Methods: Seventy-nine patients with asymptomatic ocular hypertension were randomly assigned to three groups receiving either the supplement, or latanoprost eye drops, or both in combination. Intraocular pressure and retinal blood flow were investigated in monthly intervals over 24 weeks.Results: Mirtogenol alone lowered IOP from baseline 38.1 to 29.0 mmHg after 16 weeks, with little further improvement during the following eight weeks. Latanoprost rapidly lowered IOP from baseline 37.7 to 27.2 mmHg within four weeks, without further effects thereafter. The combination of the supplement and latanoprost lowered IOP from 38.0 to 27.3 mmHg after four weeks, and further decreased IOP to 24.2 mmHg after six weeks. After 24 weeks IOP with the combination treatment (23.0 mmHg) was significantly lower than with latanoprost alone (27.2 mmHg). Mirtogenol and latanoprost individually showed comparable effects for gradually increasing central artery blood flow with treatment duration. Combination treatment showed higher systolic blood flow velocity throughout the trial period. The diastolic blood flow velocity gradually increased with treatment duration in all three groups. From twelve weeks onwards, the diastolic component with combination treatment was higher than with individual treatments.Conclusions: Mirtogenol lowered elevated IOP in patients almost as effectively as latanoprost, however, it takes much longer (24 vs 4 weeks). The combination of both was more effective for lowering IOP and the combination yielded better retinal blood flow. No serious side effects occurred during the study, apart from standard side effects in patients related to Latanoprost. These promising results warrant further research of Mirtogenol with a larger patient group.Keywords: intraocular pressure, latanoprost, mirtogenol, pycnogenol, nutrition Robert D Steigerwalt JrGianni BelcaroPaolo Morazzoniet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 471-476 (2010) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Robert D Steigerwalt Jr Gianni Belcaro Paolo Morazzoni et al Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
| description |
Robert D Steigerwalt Jr1, Gianni Belcaro1, Paolo Morazzoni2, Ezio Bombardelli2, Carolina Burki3, Frank Schönlau4 1Department of Biomedical Sciences, University of Chieti-Pescara, San Valentino, Italy; 2Indena S.p.A. Scientific Department, Milan, Italy; 3Horphag Research (UK) Ltd., Geneva, Switzerland; 4Horphag Research (UK) Ltd. South Kensington, London UKPurpose: The dietary supplement Mirtogenol® was previously shown to lower elevated intraocular pressure (IOP). We here present the effects of this supplement on IOP in comparison as well as in combination with latanoprost eye drops. Methods: Seventy-nine patients with asymptomatic ocular hypertension were randomly assigned to three groups receiving either the supplement, or latanoprost eye drops, or both in combination. Intraocular pressure and retinal blood flow were investigated in monthly intervals over 24 weeks.Results: Mirtogenol alone lowered IOP from baseline 38.1 to 29.0 mmHg after 16 weeks, with little further improvement during the following eight weeks. Latanoprost rapidly lowered IOP from baseline 37.7 to 27.2 mmHg within four weeks, without further effects thereafter. The combination of the supplement and latanoprost lowered IOP from 38.0 to 27.3 mmHg after four weeks, and further decreased IOP to 24.2 mmHg after six weeks. After 24 weeks IOP with the combination treatment (23.0 mmHg) was significantly lower than with latanoprost alone (27.2 mmHg). Mirtogenol and latanoprost individually showed comparable effects for gradually increasing central artery blood flow with treatment duration. Combination treatment showed higher systolic blood flow velocity throughout the trial period. The diastolic blood flow velocity gradually increased with treatment duration in all three groups. From twelve weeks onwards, the diastolic component with combination treatment was higher than with individual treatments.Conclusions: Mirtogenol lowered elevated IOP in patients almost as effectively as latanoprost, however, it takes much longer (24 vs 4 weeks). The combination of both was more effective for lowering IOP and the combination yielded better retinal blood flow. No serious side effects occurred during the study, apart from standard side effects in patients related to Latanoprost. These promising results warrant further research of Mirtogenol with a larger patient group.Keywords: intraocular pressure, latanoprost, mirtogenol, pycnogenol, nutrition |
| format |
article |
| author |
Robert D Steigerwalt Jr Gianni Belcaro Paolo Morazzoni et al |
| author_facet |
Robert D Steigerwalt Jr Gianni Belcaro Paolo Morazzoni et al |
| author_sort |
Robert D Steigerwalt Jr |
| title |
Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
| title_short |
Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
| title_full |
Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
| title_fullStr |
Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
| title_full_unstemmed |
Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
| title_sort |
mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects |
| publisher |
Dove Medical Press |
| publishDate |
2010 |
| url |
https://doaj.org/article/f006189deaa4460a93eedfacea0c2992 |
| work_keys_str_mv |
AT robertdsteigerwaltjr mirtogenolampregpotentiateslatanoprostinloweringintraocularpressureandimprovesocularbloodflowinasymptomaticsubjects AT giannibelcaro mirtogenolampregpotentiateslatanoprostinloweringintraocularpressureandimprovesocularbloodflowinasymptomaticsubjects AT paolomorazzoni mirtogenolampregpotentiateslatanoprostinloweringintraocularpressureandimprovesocularbloodflowinasymptomaticsubjects AT etal mirtogenolampregpotentiateslatanoprostinloweringintraocularpressureandimprovesocularbloodflowinasymptomaticsubjects |
| _version_ |
1718401342870913024 |